Athira Pharma Inc
NASDAQ:ATHA

Watchlist Manager
Athira Pharma Inc Logo
Athira Pharma Inc
NASDAQ:ATHA
Watchlist
Price: 7.48 USD 3.74% Market Closed
Market Cap: 29.5m USD

Relative Value

There is not enough data to reliably calculate the relative value of ATHA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATHA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1.1
Industry
21.5
Forward
-1.1
vs History
vs Industry
Median 3Y
-0.9
Median 5Y
-1.3
Industry
16.7
vs History
vs Industry
Median 3Y
-0.9
Median 5Y
-1.3
Industry
23
vs History
47
vs Industry
79
Median 3Y
0.5
Median 5Y
0.6
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
58
vs Industry
55
Median 3Y
0.4
Median 5Y
0.3
Industry
13.2
Forward
-0.1
vs History
53
vs Industry
52
Median 3Y
0.4
Median 5Y
0.2
Industry
16.6
Forward
-0.2
vs History
58
vs Industry
57
Median 3Y
0.4
Median 5Y
0.2
Industry
15.8
vs History
58
vs Industry
43
Median 3Y
0.4
Median 5Y
0.2
Industry
19
vs History
vs Industry
85
Median 3Y
-2.6
Median 5Y
-1.9
Industry
2

Multiples Across Competitors

ATHA Competitors Multiples
Athira Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Athira Pharma Inc
NASDAQ:ATHA
29.5m USD 0 -0.8 -0.1 -0.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.4 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.6B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.5 108.4 158.7
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
265.6B USD 4.1 14 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
142.7B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
Athira Pharma Inc
NASDAQ:ATHA
Average P/E: 24.4
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
37%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Athira Pharma Inc
NASDAQ:ATHA
Average EV/EBITDA: 439.6
Negative Multiple: -0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Athira Pharma Inc
NASDAQ:ATHA
Average EV/EBIT: 1 882.9
Negative Multiple: -0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4